CMS Finalizes GLOBE Model to Tie Medicare Drug Prices to International Benchmarks
The Centers for Medicare and Medicaid Services has finalized the GLOBE program, a five-year mandatory model that will link Medicare Part B drug prices to cost benchmarks from 19 developed nations, beginning in January 2027. The initiative focuses on medications used in oncology, rheumatology, immunology, ophthalmology, and endocrinology treatment. A parallel Part D program addressing outpatient prescription drugs remains under development.
The GLOBE initiative represents a significant shift in how Medicare reimburses injectable medications across five specialized treatment areas. By anchoring U.S. drug prices to what other wealthy nations pay, the model aims to reduce the gap between American and international pricing structures. The program's mandatory nature means participating providers and manufacturers cannot opt out during its five-year operational window beginning in 2027.
A complementary program addressing oral prescription drugs through Medicare Part D is still undergoing development, suggesting the pricing reform approach may eventually extend beyond injectable medications. The sequencing of these initiatives indicates a phased strategy to address drug cost pressures across different delivery settings and drug categories.
The GLOBE model could meaningfully affect seniors' out-of-pocket costs for expensive specialty medications while potentially influencing how pharmaceutical companies price drugs globally. Manufacturers may face pressure to adjust pricing strategies across markets, and some may reduce investment in certain drug categories. Healthcare providers in oncology and related specialties could experience revenue changes depending on how benchmark prices compare to current reimbursement rates. The program's real-world effects on drug availability, innovation incentives, and actual beneficiary access remain uncertain until implementation begins.